Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience-Reference-Cited by-同舟云学术

Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience

Published:2017-03-28 Issue:3 Volume:163 Page:587-594
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Ciccarese Mariangela^ORCID,Fabi Alessandra,Moscetti Luca,Cazzaniga Maria Elena,Petrucelli Luciana,Forcignanò Rosachiara,Lupo Laura Isabella,De Matteis Elisabetta,Chiuri Vincenzo Emanuele,Cairo Giuseppe,Febbraro Antonio,Giordano Guido,Giampaglia Marianna,Bilancia Domenico,La Verde Nicla,Maiello Evaristo,Morritti Maria,Giotta Francesco,Lorusso Vito,Latorre Agnese,Scavelli Claudio,Romito Sante,Cusmai Antonio,Palmiotti Gennaro,Surico Giammarco

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-017-4213-9.pdf

Reference33 articles.

1. Theriault LR, Carlson RW, Alfred C, Anderson BO, Burstein HJ, Edge SB, Farrar BB, Forero A, Giordano SH, Goldstein LG, Gradishar WJ, Hayes DF, Hudis CA, et al. (2013) Breast Cancer version 3.2013: featured updates to the NCNN guidelines. J Natl Compr Cancer Netw 11:753–760 (quiz 761)

2. Cardoso F, Costa A, Norton L, Senkus E, Aapro M, Andrè F et al (2014) ESO-ESMO 2th International consensus guidelines for advanced breast cancer (ABC2). Ann Oncol 25:1871–1888

3. Boneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thurlimann B, Von Euler M, Sahmoud T, Webster A, Steinberg M (2001) Anastrozole is superior to tamoxifen as first line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92(9):2247–2258

4. Nabholtz JM, Boneterre J, Buzdar A, Robertson JF, Thurlimann B (2003) Anastrozole (Arimidex) versus tamoxifen as first line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer 39(12):1684–1689

5. Mouridsen H, Gershanovich M, Sun Y, Perez Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jaenicke F, Pluzanska A, Danl M, Becquart D, Bapsy PP, Salminen E, Snyder R, Chaudri-Ross H, Lang R, Wyyld P, Bhatnagar A (2003) Phase III study of letrozole versus tamoxifen as first line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the international letrozole breast cancer group. J Clin Oncol 21(11):2101–2109

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relationship Between Daily Dose of Everolimus and Treatment Effect in Patients With Luminal HER2-negative Metastatic Breast Cancer;Anticancer Research;2023-11

2. Prevalence of acute oral mucosal damage secondary to the use of systemic antineoplastics: A systematic review and meta-analysis;Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology;2023-03

3. Safety and Efficacy of RAD001 (Everolimus) Administered Upon Relapse During or After Adjuvant Treatment in Post-menopausal Women With Hormone Receptor Positive, HER2/neu Negative Locally Advanced or Metastatic Breast Cancer (CRAD001JGR08 “MELPOMENI” study);Anticancer Research;2022-01-29

4. Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study;Cancer Investigation;2021-12-22

5. Efficacy and safety of low-dose everolimus combined with endocrine drugs for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer;Annals of Translational Medicine;2021-10